The Journal of Immunology · 2001 · 70 citations · 28 references
Veterinary MedicineImmunologyOncologyImmunizationMolecular OncologyVaccinologyCancer VaccinesDna VaccinesNucleic Acid VaccinesVaccinationVaccine EffectivenessVaccine EfficacyCancer Dna VaccinesCancer Vaccine ToxicityDeoxyribonucleic Acid (Dna) VaccineDna Cancer VaccinesDna Vector VaccinesTherapeutic Dna VaccinesTyrosine Kinase ReceptorsVaccination Efficacy
Wild-type ErbB-2 (E2) positive D2F2/E2 tumors are rejected by active vaccination with ErbB-2 DNA. However, anti-ErbB-2 Ab response can cause cardiac toxicity or interfere with cellular immunity. It will be advantageous to induce only cellular immunity by active vaccination. A panel of E2 DNA vaccines were constructed, and their vaccination efficacy was ranked as E2 > tyrosine kinase-deficient ErbB-2 (E2A) > full-length ErbB-2 targeted to the cytoplasm (cytE2) > tyrosine kinase-deficient cytE2 (cytE2A). E2A is a tyrosine kinase-deficient mutant containing a single residue substitution. CytE2 or cytE2A encodes a full-length protein that is targeted to and rapidly degraded in the cytosol by the proteasomes. Covaccination with cytE2A and GM-CSF or IL-2 DNA resulted in equivalent anti-tumor activity as E2. However, anti-ErbB-2 Ab was induced by E2 or E2A, but not cytE2 or cytE2A. Therefore, cytE2A appears to induce anti-tumor immunity without an Ab response. ErbB-2-specific CTL were detected in mice immunized with cytE2A and GM-CSF and have rejected tumor challenge. Depletion of CD8, but not CD4 T cells reduced anti-tumor immunity, indicating CTL as the effector cells. Covaccination with E2A and cytE2A induced synergistic anti-tumor activity, supporting enhanced peptide presentation from cytE2A, which was further evidenced by superior CTL activation using APCs expressing cytE2 vs E2. Taken together, cytoplasmic ErbB-2 DNA induced anti-tumor CTL, but not humoral response, demonstrating the feasibility of eliciting individual effector mechanism by targeted DNA vaccine.
28
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski Mx, Lofgren Ja, Lewis Gd et al. · PubMed · 1999 · 654 citations
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Mary L. Disis, Emanuel Calenoff, Graham McLaughlin et al. · PubMed · 1994 · 467 citations
Life Sciences, Immunology, Oncology +17